

Updated: 06/2019 PARP Approved: 06/2019

Prior Authorization Criteria Visudyne (verteporfrin)

All requests for Visudyne (verteporfrin) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

For all requests for Visudyne (verteporfrin) all of the following criteria must be met:

- The member is 18 years of age or older
- The treatment is prescribed by, or in consultation with, an ophthalmologist
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines

Coverage may be provided with a <u>diagnosis</u> of Age Related Macular Degeneration and the following criteria is met:

• The member has had a trial and failure of a vascular endothelial growth factor (VEGF) inhibitor (e.g. Avastin), or submitted a clinical reason for not having a trial of a vascular endothelial growth factor (VEGF) inhibitor (e.g. Avastin)

Coverage may be provided with a <u>diagnosis</u> of Subfoveal Choroidal Neovascularization and the following criteria is met:

• Must provide documentation showing neovascularization is due to pathologic myopia, or presumed ocular histoplasmosis

Initial Duration of Approval: 12 months

Reauthorization criteria

o Member continues to meet initial criteria for medical necessity

Reauthorization Duration of Approval: 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.



Updated: 06/2019 PARP Approved: 06/2019

VISUDYNE (verteporfrin) PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Gateway HealthSM Pharmacy Services. **FAX:** (888) 245-2049

If needed, you may call to speak to a Pharmacy Services Representative.

РНО	NE: (800) 392-1147 Monda	y through	Friday 8:30	Dam to 5:00pm		
	PROVIDER I	NFORMA	TION			
Requesting Provider:			NPI:			
Provider Specialty:			Office Contact:			
Office Address:			Office Phone:			
			Office Fa	х:		
	MEMBER IN		ΓΙΟΝ			
Member Name: DOB:						
			weight: _	pounds or	kg	
REQUESTED DRUG INFORMATION						
Medication:		Streng				
Frequency:		Durati				
Is the member currently receiving requested medication? Yes No Date Medication Initiated:						
Billing Information						
This medication will be billed:	at a pharmacy OR					
medically (if medically please provide a JCODE:						
Place of Service: Hospital Provider's office Member's home Other						
Place of Service Information						
Name:			NPI:			
Address:			Phone:			
	A FEDERAL THAT A PART A	a				
MEDICAL HISTORY (Complete for ALL requests)						
Diagnosis: ICD-10 Code:						
CUDDENT DDEVIOUS THED A DV						
CURRENT or PREVIOUS THERAPY						
Medication Name	Strength/ Frequency	Dates of Therapy		Status (Discontinued & Why	(Current)	
	<u> </u>					
	<u> </u>					
CLID						
SUP	PORTING INFORMATION	ON or CL	INICAL R	ATIONALE		
Prescribing Provider Signature Date						
Trescribing Flovio	ici Signature			Date		
			1			